Thread by @adlunam_capital

For my first thread in 2022, I’m going to talk about another #psilocybin therapy company
PHARMATHER HOLDINGS LTD (CSE : $PHRM, OTC: $PHHRF)
Ticker: $PHRM
Price: ~C$0.37
Market cap: ~C$32 M
Investment style: Speculative
cc @psychstockwatch, @shroombom1000, @MicrodoseHQ
👇

1/17 $PHRM is a clinical stage psychedelic company with focus on psychedelics use as prescription drugs.

2/17 @Pharmather_Inc is focusing on ketamine delivery via different formulations and a microneedle transdermal patch for intradermal delivery.

3/17 $PHRM is targeting indications like: mental illness including depression, schizophrenia , PTSD, Neurological disorders like Parkinson's, ALS and pain disorders like chronic and acute pain, post-operative etc.

4/17 Strategy: $PHRM is focusing on novel uses, formulations and delivery forms of ketamine and psychedelics for FDA approval

5/17 $PHRM is advancing Phase 2 clinical studies of Ketamine and KETABETTM in Parkinson’s
disease, Depression and ALS

6/17 @Pharmather_Inc is also focusing on developing of patented Microneedle patch delivering psychedelics (intradermal -> improve safety and efficacy) +

7/17 developing new uses and derivatives of psychedelics through collaborations and panaceAlTM drug Al platform

8/17 $PHRM has 2022 loaded with catalysts which include:
Microneedle Patch — Phase 1 study results for ketamine, KETABETTM, psilocybin, DMT, LSD, MDMA
ALS (Lou Gehrig’s) — Interim results for FDA Phase 2 clinical study with ketamine

9/17 Ketamine Supply — Complete manufacturing for pivotal studies and FDA registration
Parkinson’s disease — End of Phase 2 meeting with FDA for ketamine
Depression — End of Phase 2 meeting with FDA for KETABETTM

10/17 $PHRM is pioneering development of Hydrogel-forming microneedle patch for Ketamine
Microneedle patch has improved safety and efficacy, reduced risk, simple and flexible dosing for ketamine for patients.

11/17 $PHRM ‘s new ketamine therapy: Ketabet reduces side effects of ketamine therapy and reduces suicidal thoughts, addiction and abuse liability.

12/17 $PHRM has 18 granted or provisional patents and has filed application in 150+ countries.

13/17 Management: @Pharmather_Inc has qualified management who have previously led and run multiple pharma businesses

14/17 Fund raising: On Sep 28, 2021, $PHRM raised C$10M via private placement of shares and warrants with institutional investors. $PHRM issued 15,625,000 Common Shares and Warrants at C$.64 and C$.80 which was under market price at that time and stock has taken a hit coz of it…

15/17 As the company raised funds at a much higher valuation than current valuation, the current price of ~C$.35 surely seems tempting and a good entry point…

16/17 All in all, @Pharmather_Inc has multiple shots at the goal and is should surely be on ones radar if they are interested in event driven strategy for 2022 in psychedelic sector…

17/17 If you liked this thread then please quote-retweet it, follow me and consider signing up for my free newsletter to be the first to receive future research about innovative companies which have a good chance of becoming future #multibagger.
getrevue.co/profile/adluna…